Opinion: miRNAs – The new wave of molecular cancer therapeutics

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how...

Full description

Saved in:
Bibliographic Details
Published in:Translational oncology 2021-06, Vol.14 (6), p.101064-101064, Article 101064
Main Authors: Lopez-Bertoni, Hernando, Laterra, John
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.
ISSN:1936-5233
1936-5233
DOI:10.1016/j.tranon.2021.101064